Associated Papers
Physical insights guided rational design of anti-EGFR antibody to reverse the acquired resistance.
Zhang M et al.
International Journal of Biological Macromolecules, 2025
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial.
Ciardiello D et al.
Esmo Open, 2025
Investigation of Exome-Wide Tumor Heterogeneity on Colorectal Tissue-Based Single Cells.
Szakállas N et al.
International Journal of Molecular Sciences, 2025
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy.
Price T et al.
Cancer Biology & Therapy, 2020
Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer.
López-Cortés A et al.
The Pharmacogenomics Journal, 2020
Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer.
Cao W et al.
Molecular Cancer Therapeutics, 2019
Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
Tintelnot J et al.
Molecular Cancer Therapeutics, 2019
Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment.
Thomsen CB et al.
Clinical Colorectal Cancer, 2019
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Nakamura Y et al.
The Oncologist, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
Van Emburgh BO et al.
Nature Communications, 2016
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F et al.
Oncotarget, 2016
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
Sánchez-Martín FJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
Arena S et al.
Science Translational Medicine, 2016
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.
Arena S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.
Dienstmann R et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 2015
The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance.
Sickmier EA et al.
Plos One, 0
Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
Sartore-Bianchi A et al.
Handbook of Experimental Pharmacology, 0